Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

Abstract

The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions and kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

1 . A compound of Formula (II), or a pharmaceutically acceptable salt thereof; 
 wherein the compound of Formula (II) is:                          wherein:    A-B is: 
 (a) N—C;  
 (b) C—N; or  
 (c) N—N;  
   when sides d and f are double bonds, and sides e and g are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) ═N—CR 4 ═CR 4 ′—;  
 (b) ═N—CR 4 ═N—;  
 (c) ═CR 4 —N═CR 4 ′—;  
 (d) ═CR 4 —N═N—;  
 (e) ═N—N═CR 4 —; or  
 (f) ═N—N═N—;  
   R 2  and R 2′ , as defined herein taken together are:                          or R 2′  and R 5 , as defined herein, taken together with the carbon atoms to which they are attached are a cycloalkyl group or a heterocyclic ring;    R 97  is: 
 (a) hydrogen;  
 (b) alkylthio;  
 (c) alkylsulfinyl;  
 (d) alkylsulfonyl;  
 (e) cyano;  
 (f) carboxyl;  
 (g) amino;  
 (h) lower alkyl;  
 (i) haloalkyl;  
 (j) hydroxy;  
 (k) alkoxy;  
 (l) haloalkoxy;  
 (m) alkylarylalkylamino;  
 (n) aminoalkyl;  
 (o) aminoaryl;  
 (p) sulfonamido;  
 (q) alkylsulfonamido;  
 (r) arylsulfonamido;  
 (s) heterocyclic ring;  
 (t) hydroxyalkyl; or  
 (u) nitro;  
   a is an integer from 1 to 3;    when sides e and g are double bonds, and sides d and f are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) —CR 4 ═N—N═;  
 (b) —N═N—CR 4 ═;  
 (c) —CR 4 ═N—CR 4 ′═;  
 (d) —N═CR 4 —N═;  
 (e) —CR 4 ═CR 4 ′—N═;  
 (f) —N═N—N═;  
   when side g is a double bond, and sides d, e and f are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) —C(O)—O—CR 4 ═;  
 (b) —C(Q)—NR 3 —CR 4 ═;  
 (c) —C(O)—S—CR 4 ═; or  
 (d) —C(H)R 4 —C(OH)R 5 —N═;  
   when sides d is a double bond, and sides e, f and g are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) ═CR 4 —O—C(O)—;  
 (b) ═CR 4 —NR 3 —C(O)—;  
 (c) ═CR 4 —S—C(O)—; or  
 (d) ═N—C(OH)R 4 —C(H)R 5 —;  
   when sides f is a double bond, and sides d, e and g are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) —CH(R 4 )—CR 5 ═N—; or  
 (b) —C(O)—CR 4 ═CR 5 —;  
   when sides e is a double bond, and sides d, f and g are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) —N═CR 4 —CH(R 5 )—; or  
 (b) —CR 4 ═CR 5 —C(O)—;  
   when sides d, e, f and g are single bonds, —X 2 —Y 2 -Z 2 - is: 
 (a) —C(O)—CR 4 (R 4′ )—C(O)—;  
   R 1  is: 
 (a) —S(O) 2 —CH 3 ;  
 (b) —S(O) 2 —NR 8 (D 1 );  
 (c) —S(O) 2 —N(D 1 )—C(O)—CF 3 ;  
 (d) —S(O)—(NH)—NH(D 1 );  
 (e) —S(O)—(NH)—N(D 1 )—C(O)—CF 3 ;  
 (f) —P(O)(CH 3 )NH(D 1 );  
 (g) —P(O)(CH 3 ) 2 ;  
 (h) —C(S)—NH(D 1 );  
 (i) (c) —S(O)(NH)CH 3 ;  
 (j) —P(O)(CH 3 )OD 1 ; or  
 (k) —P(O)(CH 3 )NH(D 1 );  
   R 1′  at each occurrence is independently: 
 (a) hydrogen;  
 (b) halogen;  
 (c) methyl; or  
 (d) CH 2 OH;  
   R 2  is: 
 (a) lower alkyl;  
 (b) cycloalkyl;  
 (c) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: 
 (1) hydrogen;  
 (2) halo;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) lower alkyl;  
 (8) N 3 ;  
 (9) —CO 2 D 1 ;  
 (10) —CO 2 -lower alkyl;  
 (11) —(C(R 5 )(R 6 )) z —OD 1 ;  
 (12) —(C(R 5 )(R 6 )) z —O-lower alkyl;  
 (13) lower alkyl-CO 2 —R 5 ;  
 (14) —OD 1 ;  
 (15) haloalkoxy;  
 (16) amino;  
 (17) nitro;  
 (18) alkylsulfinyl; or  
 (19) heteroaryl;  
 
 (d) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: 
 (1) hydrogen;  
 (2) halo;  
 (3) lower alkyl;  
 (4) alkoxy;  
 (5) alkylthio;  
 (6) CN;  
 (7) haloalkyl, preferably CF 3 ;  
 (8) N 3 ;  
 (9) —C(R 5 )(R 6 )—OD 1 ;  
 (10) —C(R 5 )(R 6 )—O-lower alkyl; or  
 (11) alkylsulfinyl;  
 
 (e) benzoheteroaryl which includes the benzo fused analogs of (d);  
 (f) —NR 10 R 11 ;  
 (g) —SR 11 ;  
 (h) —OR 11 ;  
 (i) —R 11 ;  
 (j) alkenyl;  
 (k) alkynyl;  
 (l) unsubstituted, mono-, di-, tri- or tetra-substituted cycloalkenyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) alkoxy;  
 (3) alkylthio;  
 (4) CN;  
 (5) haloalkyl, preferably CF 3 ;  
 (6) lower alkyl;  
 (7) N 3 ;  
 (8) —CO 2 D 1 ;  
 (9) —CO 2 -lower alkyl;  
 (10) —C(R 12 )(R 13 )—OD 1 ;  
 (11) —C(R 12 )(R 13 )—O-lower alkyl;  
 (12) lower alkyl-CO 2 —R 12 ;  
 (13) benzyloxy;  
 (14) —O-(lower alkyl)-CO 2 R 12 ;  
 (15) —O-(lower alkyl)-NR 12 R 13 ; or  
 (16) alkylsulfinyl;  
 
 (m) mono-, di-, tri- or tetra-substituted heterocycloalkyl group of 5, 6 or 7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and, optionally, contains a carbonyl group or a sulfonyl group, and wherein said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 12 )(R 13 )—OD 1 ;  
 (9) —C(R 12 )(R 13 )—O-lower alkyl; or  
 (10) alkylsulfinyl;  
 
 (n) styryl, mono or di-substituted styryl, wherein the substituent are each independently: 
 (1) halo;  
 (2) alkoxy;  
 (3) alkylthio;  
 (4) CN;  
 (5) haloalkyl, preferably CF 3 ;  
 (6) lower alkyl;  
 (7) N 3 ;  
 (8) —CO 2 D 1 ;  
 (9) —CO 2 -lower alkyl;  
 (10) —C(R 12 )(R 13 )—OD 1 ;  
 (11) —C(R 12 )(R 13 )—O-lower alkyl;  
 (12) lower alkyl-CO 2 —R 12 ;  
 (13) benzyloxy;  
 (14) —O-(lower alkyl)-CO 2 R 12 ; or  
 (15) —O-(lower alkyl)-NR 12 R 13 ;  
 
 (o) phenylacetylene, mono- or di-substituted phenylacetylene, wherein the substituents are each independently: 
 (1) halo;  
 (2) alkoxy;  
 (3) alkylthio;  
 (4) CN;  
 (5) haloalkyl, preferably CF 3 ;  
 (6) lower alkyl;  
 (7) N 3 ;  
 (8) —CO 2 D 1 ;  
 (9) —CO 2 -lower alkyl;  
 (10) —C(R 12 )(R 13 )—OD 1 ;  
 (11) —C(R 12 )(R 13 )—O-lower alkyl;  
 (12) lower alkyl-CO 2 —R 12 ;  
 (13) benzyloxy;  
 (14) —O-(lower alkyl)-CO 2 R 12 ; or  
 (15) —O-(lower alkyl)-NR 12 R 13 ;  
 
 (p) fluoroalkenyl;  
 (q) mono- or di-substituted bicyclic heteroaryl of 8, 9 or 10 members, containing 2, 3, 4 or 5 heteroatoms, wherein at least one heteroatom resides on each ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and N and said substituents are each independently: 
 (1) hydrogen;  
 (2) halo;  
 (3) lower alkyl;  
 (4) alkoxy;  
 (5) alkylthio;  
 (6) CN;  
 (7) haloalkyl, preferably CF 3 ;  
 (8) N 3 ;  
 (9) —C(R 5 )(R 6 )—OD 1 ; or  
 (10) —C(R 5 )(R 6 )—O-lower alkyl;  
 
 (r) K;  
 (s) aryl;  
 (t) arylalkyl;  
 (u) cycloalkylalkyl;  
 (v) —C(O)R 11 ;  
 (u) hydrogen;  
 (v) arylalkenyl;  
 (w) arylalkoxy;  
 (x) alkoxy;  
 (y) aryloxy;  
 (z) cycloalkoxy;  
 (aa) arylthio;  
 (bb) alkylthio;  
 (cc) arylalkylthio; or  
 (dd) cycloalkylthio;  
   R 3  is: 
 (a) hydrogen;  
 (b) haloalkyl, preferably CF 3 ;  
 (c) CN;  
 (d) lower alkyl;  
 (e) —(C(R e )(R f )) p —U—V;  
 (f) K;  
 (g) unsubstituted or substituted: 
 (1) lower alkyl-Q;  
 (2) lower alkyl-O-lower alkyl-Q;  
 (3) lower alkyl-S-lower alkyl-Q;  
 (4) lower alkyl-O-Q;  
 (5) lower alkyl-S-Q;  
 (6) lower alkyl-O—V;  
 (7) lower alkyl-S—V;  
 (8) lower alkyl-O—K; or  
 (9) lower alkyl-S—K;  
 
   wherein the substituent(s) reside on the lower alkyl group; 
 (h) Q;  
 (i) alkylcarbonyl;  
 (j) arylcarbonyl;  
 (k) alkylarylcarbonyl;  
 (l) arylalkylcarbonyl;  
 (m) carboxylic ester;  
 (n) carboxamido;  
 (o) cycloalkyl;  
 (p) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: 
 (1) hydrogen;  
 (2) halo;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) lower alkyl;  
 (8) N 3 ;  
 (9) —CO 2 D 1 ;  
 (10) —CO 2 -lower alkyl;  
 (11) —(C(R 5 )(R 6 )) z —OD 1 ;  
 (12) —(C(R 5 )(R 6 )) z —O-lower alkyl;  
 (13) lower alkyl-CO 2 —R 5 ;  
 (14) —OD 1 ;  
 (15) haloalkoxy;  
 (16) amino;  
 (17) nitro; or  
 (18) alkylsulfinyl;  
 
 (q) alkenyl;  
 (r) alkynyl;  
 (s) arylalkyl;  
 (t) lower alkyl-OD 1 ;  
 (u) alkoxyalkyl;  
 (v) aminoalkyl;  
 (w) lower alkyl-CO 2 R 10 ;  
 (x) lower alkyl-C(O)NR 10 (R 10′ );  
 (y) heterocyclicalkyl; or  
 (z) heterocyclic ring-C(O)—;  
   R 4 , R 4′ , R 5  and R 5′  are each independently: 
 (a) hydrogen;  
 (b) amino;  
 (c) CN;  
 (d) lower alkyl;  
 (e) haloalkyl;  
 (f) alkoxy;  
 (g) alkylthio;  
 (h) Q;  
 (i) —O-Q;  
 (j) —S-Q;  
 (k) K;  
 (l) cycloalkoxy;  
 (m) cycloalkylthio;  
 (n) unsubstituted, mono-, or di-substituted phenyl or unsubstituted, mono-, or di-substituted benzyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) Q;  
 (9) nitro; or  
 (10) amino;  
 
 (o) unsubstituted, mono-, or di-substituted heteroaryl or unsubstituted, mono-, or di-substituted heteroarylmethyl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 6 )(R 7 )—OD 1 ;  
 (9) —C(R 6 )(R 7 )—O-lower alkyl; or  
 (10) alkylsulfinyl  
 
 (p) —CON(R 8 )(R 8 );  
 (q) —CH 2 OR 8 ;  
 (r) —CH 2 OCN;  
 (s) unsubstituted or substituted: 
 (1) lower alkyl-Q;  
 (2) —O-lower alkyl-Q;  
 (3) —S-lower alkyl-Q;  
 (4) lower alkyl-O-lower alkyl-Q;  
 (5) lower alkyl-S-lower alkyl-Q;  
 (6) lower alkyl-O-Q;  
 (7) lower alkyl-S-Q;  
 (8) lower alkyl-O—K;  
 (9) lower alkyl-S—K;  
 (10) lower alkyl-O—V; or  
 (11) lower alkyl-S—V;  
 
   wherein the substituent(s) resides on the lower alkyl; 
 (t) cycloalkyl;  
 (u) aryl;  
 (v) arylalkyl;  
 (w) cycloalkylalkyl;  
 (x) aryloxy;  
 (y) arylalkoxy;  
 (z) arylalkylthio;  
 (aa) cycloalkylalkoxy;  
 (bb) heterocycloalkyl;  
 (cc) alkylsulfonyloxy;  
 (dd) alkylsulfonyl;  
 (ee) arylsulfonyl;  
 (ff) arylsulfonyloxy;  
 (gg) —C(O)R 10 ;  
 (hh) nitro;  
 (ii) amino;  
 (jj) aminoalkyl;  
 (kk) —C(O)-alkyl-heterocyclic ring;  
 (ll) halo;  
 (mm) heterocyclic ring;  
 (nn) —CO 2 D 1 ;  
 (oo) carboxyl;  
 (pp) amidyl; or  
 (qq) alkoxyalkyl;  
   alternatively, R 4  and R 5  together with the carbons to which they are attached are: 
 (a) cycloalkyl;  
 (b) aryl; or  
 (c) heterocyclic ring;  
   alternatively, R 4  and R 4′  or R 5  and R 5′  taken together with the carbon to which they are attached are: 
 (a) cycloalkyl; or  
 (b) heterocyclic ring;  
   alternatively, R 4  and R 5 , R 4′  and R 5′ , R 4  and R 5′ , or R 4′  and R 5  when substituents on adjacent carbon atoms taken together with the carbons to which they are attached are: 
 (a) cycloalkyl;  
 (b) heterocyclic ring; or  
 (c) aryl;  
   R 6  and R 7  are each independently: 
 (a) hydrogen;  
 (b) unsubstituted, mono- or di-substituted phenyl; unsubstituted, mono- or di-substituted benzyl; unsubstituted, mono- or di-substituted heteroaryl; mono- or di-substituted heteroarylmethyl, wherein said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 14 )(R 15 )—OD 1 ; or  
 (9) —C(R 14 )(R 15 )—O-lower alkyl;  
 
 (c) lower alkyl;  
 (d) —CH 2 OR 8 ;  
 (e) CN;  
 (f) —CH 2 CN;  
 (g) haloalkyl, preferably fluoroalkyl;  
 (h) —CON(R 8 )(R 8 );  
 (i) halo; or  
 (j) —OR 8 ;  
   R 8  is: 
 (a) hydrogen;  
 (b) K; or  
 (c) R 9 ;  
   alternatively, R 5  and R 5 ′, R 6  and R 7  or R 7  and R 8  together with the carbon to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; optionally containing up to two heteroatoms selected from oxygen, S(O) o  or NR i ;    R 9  is: 
 (a) lower alkyl;  
 (b) lower alkyl-CO 2 D 1 ;  
 (c) lower alkyl-NHD 1 ;  
 (d) phenyl or mono-, di- or tri-substituted phenyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) lower alkyl-CO 2 D 1 ;  
 (6) lower alkyl-NHD 1 ;  
 (7) CN;  
 (8) CO 2 D 1 ; or  
 (9) haloalkyl, preferably fluoroalkyl;  
 
 (e) benzyl, mono-, di- or tri-substituted benzyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) lower alkyl-CO 2 D 1 ;  
 (6) lower alkyl-NHD 1 ;  
 (7) CN;  
 (8) —CO 2 D 1 ; or  
 (9) haloalkyl, preferably CF 3 ;  
 
 (f) cycloalkyl;  
 (g) K; or  
 (h) benzoyl, mono-, di-, or trisubstituted benzoyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) lower alkyl-CO 2 D 1 ;  
 (6) lower alkyl-NHD 1 ;  
 (7) CN;  
 (8) —CO 2 D 1 ; or  
 (9) haloalkyl, preferably CF 3 ;  
 
   R 10  and R 10 ′ are each independently: 
 (a) hydrogen; or  
 (b) R 11 ;  
   R 11  is: 
 (a) lower alkyl;  
 (b) cycloalkyl;  
 (c) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: 
 (1) halo;  
 (2) alkoxy;  
 (3) alkylthio;  
 (4) CN;  
 (5) haloalkyl, preferably CF 3 ;  
 (6) lower alkyl;  
 (7) N 3 ;  
 (8) —CO 2 D 1 ;  
 (9) —CO 2 -lower alkyl;  
 (10) —C(R 12 )(R 13 )—OD 1 ;  
 (11) —C(R 12 )(R 13 )—O-lower alkyl;  
 (12) lower alkyl-CO 2 D 1 ;  
 (13) lower alkyl-CO 2 R 12 ;  
 (14) benzyloxy;  
 (15) —O-(lower alkyl)-CO 2 D 1 ;  
 (16) —O-(lower alkyl)-CO 2 R 12 ; or  
 (17) —O-(lower alkyl)-NR 12 R 13 ;  
 
 (d) unsubstituted, mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 12 )(R 13 )—OD 1 ; or  
 (9) —C(R 12 )(R 13 )—O-lower alkyl;  
 
 (e) unsubstituted, mono- or di-substituted benzoheterocycle, wherein the benzoheterocycle is a 5, 6, or 7-membered ring which contains 1 or 2 heteroatoms independently selected from O, S, or N, and, optionally, a carbonyl group or a sulfonyl group, wherein said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 12 )(R 13 )—OD 1 ; or  
 (9) —C(R 12 )(R 13 )—O-lower alkyl;  
 
 (f) unsubstituted, mono- or di-substituted benzocarbocycle, wherein the carbocycle is a 5, 6, or 7-membered ring which optionally contains a carbonyl group, wherein said substituents are each independently: 
 (1) halo;  
 (2) lower alkyl;  
 (3) alkoxy;  
 (4) alkylthio;  
 (5) CN;  
 (6) haloalkyl, preferably CF 3 ;  
 (7) N 3 ;  
 (8) —C(R 12 )(R 13 )—OD 1 ; or  
 (9) —C(R 12 )(R 13 )—O-lower alkyl;  
 
 (g) hydrogen; or  
 (h) K  
   R 12  and R 13  are each independently: 
 (a) hydrogen;  
 (b) lower alkyl; or  
 (c) aryl; or  
   R 12  and R 13  together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms;    R 14  and R 15  are each independently: 
 (a) hydrogen; or  
 (b) lower alkyl; or  
   R 14  and R 15  together with the atom to which they are attached form a carbonyl, a thial, or a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms;    D 1  is: 
 (a) hydrogen or  
 (b) D;  
   D is: 
 (a) V; or  
 (b) K;  
   U is: 
 (a) oxygen;  
 (b) sulfur; or  
 (c) —N(R a )(R i )—;  
   V is: 
 (a) —NO;  
 (b) —NO 2 ; or  
 (c) hydrogen  
   K is —W aa -E b -(C(R e )(R f )) p -E c -(C(R e )(R f )) x —W d —(C(R e )(R f )) y —W i -E j -W g —(C(R e )(R f )) z —U—V;    wherein aa, b, c, d, g, i and j are each independently an integer from 0 to 3;    p, x, y and z are each independently an integer from 0 to 10;    W at each occurrence is independently: 
 (a) —C(O)—;  
 (b) —C(S)—;  
 (c) -T-;  
 (d) —(C(R e )(R f )) h —;  
 (e) alkyl;  
 (f) aryl;  
 (g) heterocyclic ring;  
 (h) arylheterocyclic ring, or  
 (i) —(CH 2 CH 2 O) q —;  
   E at each occurrence is independently: 
 (a) -T-;  
 (b) alkyl;  
 (c) aryl;  
 (d) —(C(R e )(R f )) h —;  
 (e) heterocyclic ring;  
 (f) arylheterocyclic ring; or  
 (g) —(CH 2 CH 2 O) q —;  
   h is an integer form 1 to 10;    q is an integer from 1 to 5;    R e  and R f  are each independently: 
 (a) hydrogen;  
 (b) alkyl;  
 (c) cycloalkoxy;  
 (d) halogen;  
 (e) hydroxy;  
 (f) hydroxyalkyl;  
 (g) alkoxyalkyl;  
 (h) arylheterocyclic ring;  
 (i) cycloalkylalkyl;  
 (j) heterocyclicalkyl;  
 (k) alkoxy;  
 (l) haloalkoxy;  
 (m) amino;  
 (n) alkylamino;  
 (o) dialkylamino;  
 (p) arylamino;  
 (q) diarylamino;  
 (r) alkylarylamino;  
 (s) alkoxyhaloalkyl;  
 (t) haloalkoxy;  
 (u) sulfonic acid;  
 (v) alkylsulfonic acid;  
 (w) arylsulfonic acid;  
 (x) arylalkoxy;  
 (y) alkylthio;  
 (z) arylthio;  
 (aa) cyano;  
 (bb) aminoalkyl;  
 (cc) aminoaryl;  
 (dd) alkoxy;  
 (ee) aryl;  
 (ff) arylalkyl;  
 (gg) carboxamido;  
 (hh) alkylcarboxamido;  
 (ii) arylcarboxamido;  
 (jj) amidyl;  
 (kk) carboxyl;  
 (ll) carbamoyl;  
 (mm) alkylcarboxylic acid;  
 (nn) arylcarboxylic acid;  
 (oo) alkylcarbonyl;  
 (pp) arylcarbonyl;  
 (qq) ester;  
 (rr) carboxylic ester;  
 (ss) alkylcarboxylic ester;  
 (tt) arylcarboxylic ester;  
 (uu) haloalkoxy;  
 (vv) sulfonamido;  
 (ww) alkylsulfonamido;  
 (xx) arylsulfonamido;  
 (yy) alkylsulfonyl,  
 (zz) alkylsulfonyloxy,  
 (aaa) arylsulfonyl,  
 (bbb) arylsulphonyloxy  
 (ccc) sulfonic ester;  
 (ddd) carbamoyl;  
 (eee) urea;  
 (fff) nitro;  
 (ggg) —U—V; or  
 (hhh) —(C(R′ e )(R′ f )) k —U—V or  
   R e  and R f  taken together are: 
 (a) oxo;  
 (b) thial;  
 (c) oxime; or  
 (d) hydrazone;  
   R e  and R f  taken together with the carbon atom to which they are attached are: 
 (a) heterocyclic ring;  
 (b) cycloalkyl group; or  
 (c) bridged cycloalkyl group;  
   R′ e  and R′ f  are each independently selected from R e ;    k is an integer from 1 to 3;    T at each occurrence is independently: 
 (a) a covalent bond,  
 (b) carbonyl,  
 (c) an oxygen,  
 (d) —S(O) o —; or  
 (e) —N(R a )(R i )—;  
   o is an integer from 0 to 2;    Q is: 
 (a) —C(O)—U-D 1 ;  
 (b) —CO 2 -lower alkyl;  
 (c) tetrazolyl-5-yl;  
 (d) —C(R 7 )(R 8 )(S-D 1 );  
 (e) —C(R 7 )(R 8 )(O-D 1 ); or  
 (f) —C(R 7 )(R 8 )(O-lower alkyl);  
   R a  is: 
 (a) a lone pair of electron;  
 (b) hydrogen; or  
 (c) lower alkyl;  
   R i  is: 
 (a) hydrogen;  
 (b) alkyl;  
 (c) aryl;  
 (d) alkylcarboxylic acid;  
 (e) arylcarboxylic acid;  
 (f) alkylcarboxylic ester;  
 (g) arylcarboxylic ester;  
 (h) alkylcarboxamido;  
 (i) arylcarboxamido;  
 (j) alkylsulfinyl;  
 (k) alkylsulfonyl;  
 (l) alkylsulfonyloxy,  
 (m) arylsulfinyl;  
 (n) arylsulfonyl;  
 (o) arylsulphonyloxy;  
 (p) sulfonamido;  
 (q) carboxamido;  
 (r) carboxylic ester;  
 (s) aminoalkyl;  
 (t) aminoaryl;  
 (u) —CH 2 —C(U—V)(R e )(R f );  
 (v) a bond to an adjacent atom creating a double bond to that atom; or  
 (w) —(N 2 O 2 —) − .M + , wherein M +  is an organic or inorganic cation;  
   with the proviso that the compound of Formula (II) must contain at least one oxime group and/or hydrazone group.    
     
     
         2 . A composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         3 . A method for (i) treating or reducing inflammation, pain or fever; (ii) treating a gastrointestinal disorder; (iii) improving the gastrointestinal properties of a COX-2 inhibitor; (iv) facilitating wound healing; (v) treating or reversing renal and/or respiratory toxicity; (vi) treating a disorder resulting from elevated levels of COX-2; or (vii) inhibiting platelet aggregation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of  claim 2 .  
     
     
         4 . The composition of  claim 2 , further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one therapeutic agent and at least one nitric oxide donor compound.  
     
     
         5 . The composition of  claim 4 , wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase (5-LO) inhibitor, a leukotriene B 4  receptor antagonist, a leukotriene A 4  hydrolase inhibitor, a 5-HT agonist, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, a H 2  antagonist, an antineoplastic agent, an antiplatelet agent, a thrombin inhibitor, a thromboxane inhibitor, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic, a  Helicobacter pylori  inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture of two or more thereof.  
     
     
         6 . The composition of  claim 5 , wherein the nonsteroidal antiinflammatory compound is acetaminophen, aspirin, diclofenac, ibuprofen, ketoprofen or naproxen.  
     
     
         7 . A method for (i) treating or reducing inflammation, pain or fever; (ii) treating a gastrointestinal disorder; (iii) improving the gastrointestinal properties of a COX-2 inhibitor; (iv) facilitating wound healing; (v) treating or reversing renal and/or respiratory toxicity; (vi) treating a disorder resulting from elevated levels of COX-2; or (vii) inhibiting platelet aggregation in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of  claim 4 .  
     
     
         8 . A kit comprising at least one compound of  claim 1 .  
     
     
         9 . The kit of  claim 8 , further comprising (i) at least one nitric oxide donor compound; (ii) at least one therapeutic agent; or (iii) at least one nitric oxide compound and at least one therapeutic agent.  
     
     
         10 . The kit of  claim 9 , wherein the at least one nitric oxide donor compound; the at least one therapeutic agent; or the at least one nitric oxide donor compound and at least one therapeutic agent; are in the form of separate components in the kit.